Treatment Outcomes and Associated Factors of Intravenous Colistin for Nosocomial Infections in Pediatric Patients: A Retrospective Study in a University Hospital in Thailand

被引:1
作者
Khamlek, Sunisa [1 ,2 ]
Lucksiri, Aroonrut [3 ]
Sunkonkit, Kanokkarn [4 ]
Oberdorfer, Peninnah [5 ]
Sukwuttichai, Pattarapan [3 ,6 ]
机构
[1] Chiang Mai Univ, Fac Pharm, PhDs Degree Program Pharm, Chiang Mai, Thailand
[2] Univ Phayao, Sch Pharmaceut Sci, Dept Pharmaceut Care, Div Clin Pharm, Phayao, Thailand
[3] Chiang Mai Univ, Fac Pharm, Dept Pharmaceut Care, 239 Suthep Rd, Chiang Mai 50200, Thailand
[4] Chiang Mai Univ, Fac Med, Dept Pediat, Div Pulm & Crit Care, Chiang Mai, Thailand
[5] Chiang Mai Univ, Fac Med, Dept Pediat, Div Infect Dis, Chiang Mai, Thailand
[6] Chiang Mai Univ, Fac Pharm, Pharmaceut Care Training Ctr, Dept Pharmaceut Care, Chiang Mai, Thailand
关键词
colistin; efficacy; safety; child; nosocomial infection; CRITICALLY-ILL CHILDREN; COMBINATION; EFFICACY; CRITERIA; RISK;
D O I
10.1097/INF.0000000000004450
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: This study aimed to investigate the efficacy and safety of intravenous colistin in pediatric patients with nosocomial Gram-negative bacteria infections and to determine factors associated with treatment outcomes. Methods: This retrospective study recruited patients <18 years of age receiving intravenous colistin between January 2014 and December 2018. Clinical data and treatment outcomes were reviewed, and factors associated with treatment outcomes were assessed. Results: This study included 178 patients with a median age of 3.4 years (range, 0.1-17.8). The mean +/- SD dose of colistin prescribed to patients without renal impairment was 5.1 +/- 0.6 mg/kg/day. The clinical response rate was 70.8% in patients receiving colistin for specific treatment. Infection-related mortality and crude mortality were 17.5% and 19.7%, respectively. The nephrotoxicity rate was 29.8%; approximately 70% of the episodes occurred between the 3rd and 7th day of treatment. The presence of at least 2 organ dysfunctions [adjusted hazard ratio (aHR): 7.17; 95% CI: 1.64-31.40], septic shock (aHR: 2.69; 95% CI: 1.36-5.32) and receiving chemotherapy/immunosuppressants (aHR: 2.68; 95% CI: 1.36-5.25) were observed to be associated with clinical failure. The factors observed to be associated with nephrotoxicity included hypoalbuminemia (aHR: 2.93; 95% CI: 1.26-6.78), receiving amphotericin B (aHR: 2.29; 95% CI: 1.16-4.52), vancomycin (aHR: 3.36; 95% CI: 1.50-7.56) and vasopressors (aHR: 2.57; 95% CI: 1.27-5.21). Conclusion: Colistin is generally effective in the treatment of nosocomial Gram-negative bacteria infections in pediatric patients. Close monitoring of renal function should be considered, especially in high-risk patients. Optimal dosage regimens for pediatric populations to promote more favorable clinical outcomes and minimize nephrotoxicity require further investigation.
引用
收藏
页码:1054 / 1060
页数:7
相关论文
共 38 条
  • [1] Carbapenem-Resistant Gram-Negative Bacterial Infections in Children
    Aguilera-Alonso, David
    Escosa-Garcia, Luis
    Saavedra-Lozano, Jesus
    Cercenado, Emilia
    Baquero-Artigao, Fernando
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [2] Modified RIFLE criteria in critically ill children with acute kidney injury
    Akcan-Arikan, A.
    Zappitelli, M.
    Loftis, L. L.
    Washburn, K. K.
    Jefferson, L. S.
    Goldstein, S. L.
    [J]. KIDNEY INTERNATIONAL, 2007, 71 (10) : 1028 - 1035
  • [3] [Anonymous], 2013, Performance standards for antimicrobial susceptibility testing. Twenty-third informal supplement. M100-S23
  • [4] Population Pharmacokinetics and Outcomes of Critically Ill Pediatric Patients Treated with Intravenous Colistin at Higher Than Recommended Doses
    Antachopoulos, Charalampos
    Geladari, Anastasia
    Landersdorfer, Cornelia B.
    Volakli, Eleni
    Ilia, Stavroula
    Gikas, Evangelos
    Gika, Helen
    Sdougka, Maria
    Nation, Roger L.
    Roilides, Emmanuel
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (06)
  • [5] The evaluation of safety and efficacy of colistin use in pediatric intensive care unit: Results from two reference hospitals and review of literature
    Bal, Zumrut Sahbudak
    Can, Fulya Kamit
    Yazici, Pinar
    Anil, Ayse Berna
    Duyu, Muhterem
    Ciftdogan, Dilek Yilmaz
    Yilmaz, Ozkalay Nisel
    Cilli, Feriha
    Karapinar, Bulent
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (05) : 370 - 375
  • [6] Efficacy and safety of colistin loading dose: a meta-analysis
    Bellos, Ioannis
    Pergialiotis, Vasilios
    Frountzas, Maximos
    Kontzoglou, Konstantinos
    Daskalakis, Georgios
    Perrea, Despina N.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (07) : 1689 - 1698
  • [7] Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections
    Cheng, Chien-Yu
    Sheng, Wang-Huei
    Wang, Jann-Tay
    Chen, Yee-Chun
    Chang, Shan-Chwen
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (03) : 297 - 300
  • [8] Appropriate use of colistin in neonates, infants and children: Interim guidance
    Chibabhai, Vindana
    Bekker, Adrie
    Black, Marianne
    Demopoulos, Despina
    Dramowski, Angela
    Plessis, Nicolette M. du
    Pillay-Fuentes, Veshni
    Nana, Trusha
    Rabie, Helena
    Reubenson, Gary
    Thomas, Reenu
    [J]. SOUTHERN AFRICAN JOURNAL OF INFECTIOUS DISEASES, 2023, 38 (01)
  • [9] Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children
    Chiotos, Kathleen
    Hayes, Molly
    Gerber, Jeffrey S.
    Tamma, Pranita D.
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2020, 9 (01) : 56 - 66
  • [10] Clinical and Laboratory Standards Institute (CLSI), 2020, CLSI M100-ED30:2020 Performance Standards for Antimicrobial Susceptibility Testing, V30th Edition